India revokes patent on Merck & Co asthma drug

MUMBAI Tue Dec 11, 2012 7:24pm IST

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009. REUTERS/Jeff Zelevansky/Files

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009.

Credit: Reuters/Jeff Zelevansky/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - India has revoked a patent granted to an asthma drug made by Schering Corp, later bought by U.S.-based Merck & Co (MRK.N), citing lack of invention, after Indian drugmaker Cipla Ltd (CIPL.NS) challenged an earlier decision.

The move is the latest in a series of patent cancellations by India, where generic medicines account for more than 90 percent of drug sales by value and whose huge potential to western drugmakers is undermined by intellectual property issues.

Earlier this year, India revoked Pfizer Inc's (PFE.N) (PFIZ.NS) patent on cancer drug Sutent, while an Indian patents appeal board overturned Roche Holding AG's (ROG.VX) patent on hepatitis C drug Pegasys.

The aerosol suspension formulation of the asthma drug, which won an Indian patent last year, combines three molecules: mometasone furoate, formoterol and heptaflouropropane. It was not immediately clear if Merck markets this drug under a specific brand name in India.

T.V. Madhusudhan, India's assistant controller of patents and design, said the patent-holder did not show an "inventive step" for the drug, either on individual parameters or in its entirety.

The ruling was posted on Tuesday on the website of the Indian patents office.

A similar asthma treatment, Dulera, lost its Indian patent held by Novartis AG (NOVN.VX) in 2010.

Officials at Merck could not immediately be reached for comment by Reuters.

(Reporting by Kaustubh Kulkarni; Editing by Tony Munroe and David Holmes)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Economic Pulse

REUTERS SHOWCASE

Political Pulse

Political Pulse

100 days of Modi: Good for business, not so good for marginalised groups.  Full Article 

Segway in India

Segway in India

Segway’s India business pegs hope on tech-savvy Modi  Full Article 

Best Economy

Best Economy

Swiss economy most competitive once again; EU, U.S., Japan improve.  Full Article 

Power Outage

Power Outage

Mumbai hit by power cuts  Full Article 

Commodities

Commodities

Gold imports, premiums to jump on festive demand - top refiner  Full Article 

Economic Worries

Economic Worries

Pakistan's promises to IMF in doubt as protests sap economy   Full Article 

Islamic Finance

Islamic Finance

Basel III deposit challenge looms over Islamic banks   Full Article 

Antitrust Probes

Antitrust Probes

U.S. business lobby says concerned China antitrust probes unfair.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage